NCT03669601 (ATRiUM) is a Phase 1 clinical trial of AZD6738 in Cancer, sponsored by CCTU- Cancer Theme.

Who is sponsoring NCT03669601?

NCT03669601 is sponsored by CCTU- Cancer Theme.

What drugs are being tested in NCT03669601?

Interventions in NCT03669601: AZD6738, Gemcitabine.

Is NCT03669601 still recruiting?

NCT03669601 is currently status unknown. Last updated 4 June 2021.

Last reviewed 2021-06-04 · How we verify

NCT03669601: ATRiUM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD6738 & Gemcitabine as Combination Therapy

Status unknown Phase 1 Last updated 4 June 2021

What this trial tests

Phase 1 trial testing AZD6738 in Cancer in 55 participants. Status unknown.

Timeline

15 October 2019

Primary endpoint
30 September 2023

30 September 2024

Quick facts

Lead sponsor	CCTU- Cancer Theme
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	15 October 2019
Primary completion	30 September 2023
Estimated completion	30 September 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

AZD6738 (azd6738) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

CCTU- Cancer Theme — full company profile →

Who can join

16 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A dose escalation trial to assess the safety of AZD6738 in combination with gemcitabine in participants with advanced solid tumours.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. · · 2020 · cited 192× · PMID 32459988 · DOI 10.1016/j.molcel.2020.04.035
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
Perkhofer L, Gout J, Roger E, Kude de Almeida F, et al · · 2021 · cited 147× · PMID 32855305 · DOI 10.1136/gutjnl-2019-319984
Leveraging the replication stress response to optimize cancer therapy.
Cybulla E, Vindigni A. · · 2023 · cited 109× · PMID 36323800 · DOI 10.1038/s41568-022-00518-6
Progress towards a clinically-successful ATR inhibitor for cancer therapy.
Barnieh FM, Loadman PM, Falconer RA. · · 2021 · cited 97× · PMID 34909652 · DOI 10.1016/j.crphar.2021.100017
Exploiting DNA repair defects in colorectal cancer.
Reilly NM, Novara L, Di Nicolantonio F, Bardelli A. · · 2019 · cited 96× · PMID 30714316 · DOI 10.1002/1878-0261.12467
Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
Ngoi NYL, Pham MM, Tan DSP, Yap TA. · · 2021 · cited 78× · PMID 34215565 · DOI 10.1016/j.trecan.2021.06.002
Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology.
Leroux C, Konstantinidou G. · · 2021 · cited 49× · PMID 33672917 · DOI 10.3390/cancers13040799

Verify or expand the search:

Other trials of AZD6738

Trials testing the same drug.

NCT04298021 — DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer · Phase 2 · active not recruiting
NCT04298008 — AZD6738 Plus Durvalumab in Biliary Tract Cancer · Phase 2 · recruiting
NCT03770429 — AZD6738 for Patients With Progressive MDS or CMML · Phase 1 · active not recruiting
NCT03780608 — This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): · Phase 2 · unknown
NCT03428607 — Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] · Phase 2 · completed

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other CCTU- Cancer Theme trials

Trials by the same sponsor.

NCT04761146 — A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer · NA · unknown
NCT05097378 — Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma · Phase 2 · unknown
NCT04285242 — Metabolic and Immunological Phenotyping in Patients With Cancer · unknown
NCT03741426 — WIRE - Novel Treatments in Renal Cell Cancer · Phase 2 · unknown
NCT04107168 — Microbiome Immunotherapy Toxicity and Response Evaluation · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03669601 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CCTU- Cancer Theme
Last refreshed: 4 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03669601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing